MedTrace Logo

Safety Study of Passive Immunization for Patients With Mild to Moderate Alzheimer's Disease

NCT00174525 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2012-05-09

No results posted yet for this study

Summary

This research study will assess whether AAB-001 is safe, well tolerated and effective for use in patients with Alzheimer's Disease. AAB-001 is a new drug that is not available outside this study. AAB-001 is an antibody (a type of protein usually produced by white blood cells to destroy other substances in the body). In Alzheimer's disease a protein called amyloid gathers in the brain and is thought to cause symptoms like memory loss and confusion. It is hoped that AAB-001 will attach to the amyloid protein in your brain and help your body to remove it.

Conditions

Interventions

DRUG

AAB-001

Sponsors & Collaborators

  • Pharmacology Research Institute

    lead OTHER

Principal Investigators

  • Daniel E. Grosz, MD · Pharmacology Research Institute, Northridge

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Completion
2008-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00174525 on ClinicalTrials.gov